通过Z3571抑制TRPC6:一种基于结构的策略,用于改善慢性脏病中球体和管状功能障碍
Lei Zhou1, Xueying Wang2, Li Ren1
1Department of Pharmacy, College of Chemistry & Pharmacy, Northwest A&F University, Yangling, Shaanxi 712100, China; Shaanxi Key Laboratory of Natural Products & Chemical Biology, Northwest A&F University, Yangling, Shaanxi 712100, China.
Biochemical pharmacology
|November 23, 2025
概括
一种新型抑制剂,Z3571,有效向TRPC6通道,通过改善球和管状功能,为慢性病 (CKD) 提供了有前途的新疗法.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 慢性病 (CKD) 涉及球体和管状功能障碍,过渡受体潜在的正规6 (TRPC6) 通道是关键的治疗标.
- 开发高度特定的TRPC6抑制剂对于有效的CKD治疗至关重要,但具有挑战性.
研究的目的:
- 确定和描述一种新型的,高度选择性的TRPC6通道抑制剂,用于CKD的潜在治疗应用.
- 在病的临床前模型中评估已识别的抑制剂的疗效和药理动力学特性.
主要方法:
- 在对15万种化合物的高通量选中,确定了TRPC6抑制剂.
- 候选人验证涉及微尺度热泳,成像,以及细胞损伤,纤维化和焦点细分样硬化 (FSGS) 的体外/体内模型.
- 药物动力学分析,TRPC6淘汰赛研究和局部定向突变发生证实了标特异性和结合相互作用.
主要成果:
- Z3571成为TRPC6抑制剂的顶级候选者,具有高结合亲和力和强大的选择性抑制 (TRPC3 / TRPC7的100倍).
- 在FSGS和纤维化的体外和体外模型中,Z3571显示出显著的治疗效果.
- 药物动力学分析显示了有利的口服生物可用性,代谢稳定性和脏积累,在TRPC6依赖模型中证实了目标活性.
结论:
- Z3571是一种高度选择性的,口服可生物利用的TRPC6抑制剂,在CKD临床前模型中已证明有效.
- 在慢性脏疾病中,Z3571代表了一种有前途的向治疗候选药物,用于控制慢性脏疾病中的淋巴细胞和管状功能障碍.
相关概念视频
01:28Renal Drug Excretion: Tubular Secretion
744
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
744
01:15Drug Elimination by Renal Route: Tubular Secretion
3.2K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
3.2K
01:25Renal Drug Excretion: Tubular Reabsorption
710
Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
710
01:22Drug Elimination by Renal Route: Tubular Reabsorption
4.8K
During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...
4.8K
01:28Chronic Kidney Disease III: Interprofessional Care
326
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
326